Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Autor: Emily Chan, Jeffrey R. Infante, Hiroshi Kodaira, Suzanne F. Jones, Whitney P Kirschbrown, Huali Wu, Wooin Lee, Johanna C. Bendell, William C. Zamboni, Mace L. Rothenberg, Beth A. Zamboni, Howard A. Burris, Vicki L. Keedy, Satoshi Ikeda
Rok vydání: 2019
Předmět:
Zdroj: International Journal of Nanomedicine
ISSN: 1178-2013
DOI: 10.2147/ijn.s207276
Popis: IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors associated with interpatient variability in the pharmacokinetics and pharmacodynamics of IHL-305 in patients with advanced solid tumors. IHL-305 was administered intravenously once every 4 weeks as part of a Phase I study. Pharmacokinetic studies of the liposomal sum total CPT-11, released CPT-11, SN-38, SN-38G, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin, and 7-ethyl-10-[4-amino-1-piperidino]-carbonyloxycamptothecin in plasma were performed. Noncompartmental and compartmental pharmacokinetic analyses were conducted using pharmacokinetic data for sum total CPT-11. The pharmacokinetic variability of IHL-305 is associated with linear and nonlinear clearance. Patients whose age and body composition (ratio of total body weight to ideal body weight [TBW/IBW]) were greater than the median age and TBW/IBW of the study had a 1.7-fold to 2.6-fold higher ratio of released CPT-11 area under the concentration versus time curve (AUC) to sum total CPT-11 AUC. Patients aged
Databáze: OpenAIRE
Externí odkaz: